Cargando…
Feasibility and safety of high-dose adenosine perfusion cardiovascular magnetic resonance
INTRODUCTION: Adenosine is the most widely used vasodilator stress agent for Cardiovascular Magnetic Resonance (CMR) perfusion studies. With the standard dose of 140 mcg/kg/min some patients fail to demonstrate characteristic haemodynamic changes: a significant increase in heart rate (HR) and mild d...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2996376/ https://www.ncbi.nlm.nih.gov/pubmed/21080924 http://dx.doi.org/10.1186/1532-429X-12-66 |
_version_ | 1782193196546129920 |
---|---|
author | Karamitsos, Theodoros D Ntusi, Ntobeko AB Francis, Jane M Holloway, Cameron J Myerson, Saul G Neubauer, Stefan |
author_facet | Karamitsos, Theodoros D Ntusi, Ntobeko AB Francis, Jane M Holloway, Cameron J Myerson, Saul G Neubauer, Stefan |
author_sort | Karamitsos, Theodoros D |
collection | PubMed |
description | INTRODUCTION: Adenosine is the most widely used vasodilator stress agent for Cardiovascular Magnetic Resonance (CMR) perfusion studies. With the standard dose of 140 mcg/kg/min some patients fail to demonstrate characteristic haemodynamic changes: a significant increase in heart rate (HR) and mild decrease in systolic blood pressure (SBP). Whether an increase in the rate of adenosine infusion would improve peripheral and, likely, coronary vasodilatation in those patients is unknown. The aim of the present study was to assess the tolerance and safety of a high-dose adenosine protocol in patients with inadequate haemodynamic response to the standard adenosine protocol when undergoing CMR perfusion imaging. METHODS: 98 consecutive patients with known or suspected coronary artery disease (CAD) underwent CMR perfusion imaging at 1.5 Tesla. Subjects were screened for contraindications to adenosine, and an electrocardiogram was performed prior to the scan. All patients initially received the standard adenosine protocol (140 mcg/kg/min for at least 3 minutes). If the haemodynamic response was inadequate (HR increase < 10 bpm or SBP decrease < 10 mmHg) then the infusion rate was increased up to a maximum of 210 mcg/kg/min (maximal infusion duration 7 minutes). RESULTS: All patients successfully completed the CMR scan. Of a total of 98 patients, 18 (18%) did not demonstrate evidence of a significant increase in HR or decrease in SBP under the standard adenosine infusion rate. Following the increase in the rate of infusion, 16 out of those 18 patients showed an adequate haemodynamic response. One patient of the standard infusion group and two patients of the high-dose group developed transient advanced AV block. Significantly more patients complained of chest pain in the high-dose group (61% vs. 29%, p = 0.009). On multivariate analysis, age > 65 years and ejection fraction < 57% were the only independent predictors of blunted haemodynamic responsiveness to adenosine. CONCLUSIONS: A substantial number of patients do not show adequate peripheral haemodynamic response to standard-dose adenosine stress during perfusion CMR imaging. Age and reduced ejection fraction are predictors of inadequate response to standard dose adenosine. A high-dose adenosine protocol (up to 210 mcg/kg/min) is well tolerated and results in adequate haemodynamic response in nearly all patients. |
format | Text |
id | pubmed-2996376 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-29963762010-12-03 Feasibility and safety of high-dose adenosine perfusion cardiovascular magnetic resonance Karamitsos, Theodoros D Ntusi, Ntobeko AB Francis, Jane M Holloway, Cameron J Myerson, Saul G Neubauer, Stefan J Cardiovasc Magn Reson Research INTRODUCTION: Adenosine is the most widely used vasodilator stress agent for Cardiovascular Magnetic Resonance (CMR) perfusion studies. With the standard dose of 140 mcg/kg/min some patients fail to demonstrate characteristic haemodynamic changes: a significant increase in heart rate (HR) and mild decrease in systolic blood pressure (SBP). Whether an increase in the rate of adenosine infusion would improve peripheral and, likely, coronary vasodilatation in those patients is unknown. The aim of the present study was to assess the tolerance and safety of a high-dose adenosine protocol in patients with inadequate haemodynamic response to the standard adenosine protocol when undergoing CMR perfusion imaging. METHODS: 98 consecutive patients with known or suspected coronary artery disease (CAD) underwent CMR perfusion imaging at 1.5 Tesla. Subjects were screened for contraindications to adenosine, and an electrocardiogram was performed prior to the scan. All patients initially received the standard adenosine protocol (140 mcg/kg/min for at least 3 minutes). If the haemodynamic response was inadequate (HR increase < 10 bpm or SBP decrease < 10 mmHg) then the infusion rate was increased up to a maximum of 210 mcg/kg/min (maximal infusion duration 7 minutes). RESULTS: All patients successfully completed the CMR scan. Of a total of 98 patients, 18 (18%) did not demonstrate evidence of a significant increase in HR or decrease in SBP under the standard adenosine infusion rate. Following the increase in the rate of infusion, 16 out of those 18 patients showed an adequate haemodynamic response. One patient of the standard infusion group and two patients of the high-dose group developed transient advanced AV block. Significantly more patients complained of chest pain in the high-dose group (61% vs. 29%, p = 0.009). On multivariate analysis, age > 65 years and ejection fraction < 57% were the only independent predictors of blunted haemodynamic responsiveness to adenosine. CONCLUSIONS: A substantial number of patients do not show adequate peripheral haemodynamic response to standard-dose adenosine stress during perfusion CMR imaging. Age and reduced ejection fraction are predictors of inadequate response to standard dose adenosine. A high-dose adenosine protocol (up to 210 mcg/kg/min) is well tolerated and results in adequate haemodynamic response in nearly all patients. BioMed Central 2010-11-16 /pmc/articles/PMC2996376/ /pubmed/21080924 http://dx.doi.org/10.1186/1532-429X-12-66 Text en Copyright ©2010 Karamitsos et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Karamitsos, Theodoros D Ntusi, Ntobeko AB Francis, Jane M Holloway, Cameron J Myerson, Saul G Neubauer, Stefan Feasibility and safety of high-dose adenosine perfusion cardiovascular magnetic resonance |
title | Feasibility and safety of high-dose adenosine perfusion cardiovascular magnetic resonance |
title_full | Feasibility and safety of high-dose adenosine perfusion cardiovascular magnetic resonance |
title_fullStr | Feasibility and safety of high-dose adenosine perfusion cardiovascular magnetic resonance |
title_full_unstemmed | Feasibility and safety of high-dose adenosine perfusion cardiovascular magnetic resonance |
title_short | Feasibility and safety of high-dose adenosine perfusion cardiovascular magnetic resonance |
title_sort | feasibility and safety of high-dose adenosine perfusion cardiovascular magnetic resonance |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2996376/ https://www.ncbi.nlm.nih.gov/pubmed/21080924 http://dx.doi.org/10.1186/1532-429X-12-66 |
work_keys_str_mv | AT karamitsostheodorosd feasibilityandsafetyofhighdoseadenosineperfusioncardiovascularmagneticresonance AT ntusintobekoab feasibilityandsafetyofhighdoseadenosineperfusioncardiovascularmagneticresonance AT francisjanem feasibilityandsafetyofhighdoseadenosineperfusioncardiovascularmagneticresonance AT hollowaycameronj feasibilityandsafetyofhighdoseadenosineperfusioncardiovascularmagneticresonance AT myersonsaulg feasibilityandsafetyofhighdoseadenosineperfusioncardiovascularmagneticresonance AT neubauerstefan feasibilityandsafetyofhighdoseadenosineperfusioncardiovascularmagneticresonance |